Skip to content
Tuesday 18 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,728.04
+0.07%
DAX
26,128.36
-0.80%
CAC 40
8,509.36
-0.82%
STOXX 50
6,468.17
-0.95%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Monday 15 March 2021 7:31 am  |  Updated:  Monday 15 March 2021 7:35 am

Netherlands and Ireland suspend rollout of Astrazeneca jab

By: Poppy Wood

Add as a preferred source on Google

The Netherlands and Ireland have joined a growing list of countries that have temporarily suspended the rollout of the Astrazeneca vaccine over possible side effects.

Ireland announced the two-week ban yesterday after Norway reported that one person had died and three had been admitted to hospital after receiving the shot.

Dr Karina Butler, head of the National Immunisation Advisory Committee (Niac), said the country had taken the decision after Norway reported a “cluster of four serious, very rare, very serious clotting events… that would normally be involved and in younger people.”

“These very small but very rare serious events in people that you might not otherwise expect it, that raised a signal, a safety signal,” she said.

The Netherlands followed suit this morning, announcing a similar two-week ban on the Astrazeneca vaccine.

In a statement, the Dutch government said it was acting out of precaution following reports of possible serious side effects across the continent.

“We can’t allow any doubts about the vaccine,” Dutch Health Minister Hugo de Jonge said. “We have to make sure everything is right, so it is wise to pause for now.”

Thailand, Denmark, Iceland and Norway all suspended vaccinations using the Astrazeneca jab last week during an investigation into a blood clot-related death of a patient in Denmark.

Various other European countries, including Italy and Austria, have temporarily stopped using two different batches of the Astrazeneca vaccine, after reports of a “serious adverse event” linked to one batch in Italy, and a death and illness in Austria related to another batch.

Read more

Astrazeneca explores $400bn megadeal with US rival 

AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.

The European Medicines Agency (EMA) said on Friday there was no evidence of a link between the events and the jabs, stressing that “the vaccine’s benefits currently still outweigh the risks”. It urged countries to continue with their vaccination campaigns.

It added that the number of blood clots in people who have received the Astrazeneca vaccine is no higher than that seen in the general population. So far, 22 blood clots have been reported among the 3m people who have received the Astrazeneca jab as of 9 March.

Astrazeneca has insisted there is no evidence of an increased risk of clotting due to its Covid vaccine, made in collaboration with the University of Oxford. 

Scepticism around the Astrazeneca vaccine has continued to amplify after false reports in German media earlier this year relating to its efficacy among older patients.

Erroneous reports in various German media outlets in January claimed the vaccine was only eight per cent effective in over-65s.

German officials later U-turned on the figure, suggesting it had been a miscommunication from government ministers. But the headlines were enough to sow public mistrust in the vaccine across the continent. 

Facebook this morning announced it will label all vaccine-related posts after the social media platform was accused of allowing misinformation to run rife.

In a blog post, Facebook said it will also launch a tool providing users with information about where to get Covid-19 vaccines and adding a Covid-19 information area to its photo-sharing site Instagram.

Read more

Astrazeneca share price tumbles on $400bn megamerger talks

Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Politics

Related Topics

  • Coronavirus
  • Vaccine

Trending Articles

  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

  • Jobless Banquet: Youth unemployment surge ‘sends Neets to KFC’

  • US bond market jitters spark UK economy recession warning

  • Monzo chair makes early exit after boardroom rift

  • Aldi boss wades into supermarket ‘price-gouging’ row

More from Morning Wire

  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
  • ISG Event to Spotlight Strategies for the AI-Driven Autonomous Enterprise

    Business Wire
  • As it happened: UK stocks cool after Astrazeneca drags; Trump and Iran clash over peace talks

    FTSE 100 Live
    Donald Trump speaking at a desk, gesturing with hands, wearing a dark suit and red tie.
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • London-listed firm cheers surge in demand for ‘dog wash machines’

    Retail
    Golden Retriever sitting on a grassy park field with a bright blue sky backdrop, embodying joy and companionship.
  • ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook